Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases

被引：0
|
作者：
Saburi, Masuho [1 ]
Nishikawa, Takumi [1 ]
Miyazaki, Yasuhiko [1 ]
Kohno, Kazuhiro [2 ]
Sakata, Masanori [3 ]
Okuhiro, Kazuki [3 ]
Nakayama, Toshiyuki [2 ]
Ohtsuka, Eiichi [1 ]
Ogata, Masao [2 ,3 ]
机构：
[1] Oita Prefectural Hosp, Dept Hematol, 8-1 Bunyo 2 Chome, Oita City, Oita 8708511, Japan
[2] Oita Kouseiren Tsurumi Hosp, Dept Hematol, Oita, Japan
[3] Oita Univ Hosp, Dept Hematol, Oita, Japan
来源：
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY | 2024年 / 64卷 / 02期
关键词：
chronic lymphocytic leukemia; small lymphocytic lymphoma; venetoclax; rituximab; Japanese; OPEN-LABEL; PHASE-3; CHEMOIMMUNOTHERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE;
D O I：
10.3960/jslrt.24014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：152 / 155
页数：4
相关论文
共 50 条
  • [1] Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Lei, Matthew M.
    Sorial, Mark N.
    Lou, Uvette
    Yu, Michelle
    Medrano, Andrea
    Ford, Josie
    Nemec, Ronald A.
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 653 - 659
  • [2] The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
    Schieber, Michael
    Ma, Shuo
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 9 - 17
  • [3] Real-world time to discontinuation of first-line venetoclax plus binutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023,
  • [4] Real-world time to discontinuation of first-line venetoclax plus obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, : 1227 - 1235
  • [5] Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience
    Laurenti, Luca
    Scarfo, Lydia
    Frustaci, Anna Maria
    Sanna, Alessandro
    Iannella, Emilia
    Caira, Morena
    Finsinger, Paola
    Schifano, Silvia
    Neri, Benedetta
    Molica, Stefano
    Mauro, Francesca Romana
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 621 - 630
  • [6] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shibayama, Hirohiko
    Teshima, Takanori
    Choi, Ilseung
    Hatake, Kiyohiko
    Sekiguchi, Naohiro
    Yoshinari, Nozomi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
  • [7] Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma
    Chang, Julie E.
    Wang, Tuo
    Kim, KyungMann
    Folstad, Matthew
    Endres, Mariah
    Howard, Mitch
    Kenkre, Vaishalee
    Fletcher, Christopher
    Rajguru, Saurabh
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1456 - 1464
  • [8] Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shadman, Mazyar
    Salkar, Monika
    Srivastava, Bhavini
    Karve, Sudeep
    Emond, Bruno
    Gogna, Priyanka
    Manceur, Ameur M.
    Lafeuille, Marie-Helene
    Rava, Andrew
    Sun, Haiyan
    Howarth, Amanda
    Tomicki, Samantha
    Agatep, Barnabie
    Jones, Barton
    Franceschini, Erin
    Saifan, Chadi
    Bacchus, Shaffee
    Roeker, Lindsey
    Stephens, Deborah M.
    LEUKEMIA & LYMPHOMA, 2024, : 44 - 53
  • [9] BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study
    Roeker, Lindsey E.
    Han, Yi
    Teschemaker, Anna
    Mato, Anthony R.
    Thompson, Meghan C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (04) : 720 - 723
  • [10] Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
    Huntington, Scott F.
    Cheng, Wendy Y.
    Sarpong, Eric M.
    Leng, Siyang
    Farooqui, Mohammed Z. H.
    Agu, Uchechukwu Samuel
    Catillon, Maryaline
    Lejeune, Dominique
    Downes, Nathaniel
    Matay, Lisa
    Duh, Mei Sheng
    De Nigris, Enrico
    LEUKEMIA & LYMPHOMA, 2024, : 932 - 942
12345